Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angus G Jones

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Diabetes Care|May 20, 2026
Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation StudyKatherine G Young, Andrew P McGovern, Rhian Hopkins, et al.
Diabetes Care|February 2, 2018
Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor TherapyJohn M Dennis, Beverley M Shields, Anita V Hill, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitorsKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
The Lancet. Digital Health|November 25, 2022
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort studyJohn M Dennis, Katherine G Young, Andrew P McGovern, et al.
Communications Medicine|October 4, 2023
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic reviewKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
Medrxiv : the Preprint Server for Health Sciences|October 9, 2023
Clinical prediction models combining routine clinical measures identify participants with youth-onset diabetes who maintain insulin secretion in the range associated with type 2 diabetes: The SEARCH for Diabetes in Youth StudyAngus G Jones, Beverley M Shields, Richard A Oram, et al.
Diabetes Care|March 20, 2019
Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by <i>SLC29A4</i>) and Organic Cation Transporter 1 (OCT1) (Encoded by <i>SLC22A1</i>) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT StudyAdem Y Dawed, Kaixin Zhou, Nienke van Leeuwen, et al.
Diabetes Care|January 22, 2024
Clinical Prediction Models Combining Routine Clinical Measures Have High Accuracy in Identifying Youth-Onset Type 2 Diabetes Defined by Maintained Endogenous Insulin Secretion: The SEARCH for Diabetes in Youth StudyAngus G Jones, Beverley M Shields, Richard A Oram, et al.
The Journal of Clinical Endocrinology and Metabolism|March 11, 2026
Relative maternal protection against type 1 diabetes: a combined analysis of five observational studiesLowri A Allen, Peter N Taylor, Annelie Carlsson, et al.
Diabetologia|February 22, 2024
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesPedro Cardoso, Katie G Young, Anand T N Nair, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Diabetes Care|May 20, 2026
Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation StudyKatherine G Young, Andrew P McGovern, Rhian Hopkins, et al.
Diabetes Care|February 2, 2018
Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor TherapyJohn M Dennis, Beverley M Shields, Anita V Hill, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitorsKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
The Lancet. Digital Health|November 25, 2022
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort studyJohn M Dennis, Katherine G Young, Andrew P McGovern, et al.
Communications Medicine|October 4, 2023
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic reviewKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
Medrxiv : the Preprint Server for Health Sciences|October 9, 2023
Clinical prediction models combining routine clinical measures identify participants with youth-onset diabetes who maintain insulin secretion in the range associated with type 2 diabetes: The SEARCH for Diabetes in Youth StudyAngus G Jones, Beverley M Shields, Richard A Oram, et al.
Diabetes Care|March 20, 2019
Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by <i>SLC29A4</i>) and Organic Cation Transporter 1 (OCT1) (Encoded by <i>SLC22A1</i>) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT StudyAdem Y Dawed, Kaixin Zhou, Nienke van Leeuwen, et al.
Diabetes Care|January 22, 2024
Clinical Prediction Models Combining Routine Clinical Measures Have High Accuracy in Identifying Youth-Onset Type 2 Diabetes Defined by Maintained Endogenous Insulin Secretion: The SEARCH for Diabetes in Youth StudyAngus G Jones, Beverley M Shields, Richard A Oram, et al.
The Journal of Clinical Endocrinology and Metabolism|March 11, 2026
Relative maternal protection against type 1 diabetes: a combined analysis of five observational studiesLowri A Allen, Peter N Taylor, Annelie Carlsson, et al.
Diabetologia|February 22, 2024
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesPedro Cardoso, Katie G Young, Anand T N Nair, et al.
Pageof 10